149 related articles for article (PubMed ID: 21575929)
1. Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications.
Al Ameri A; Jabbour E; Garcia-Manero G; O'Brien S; Faderl S; Ravandi F; Shan J; Pierce S; Cortes J; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):237-41. PubMed ID: 21575929
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome.
Gonzalez-Porras JR; Cordoba I; Such E; Nomdedeu B; Vallespi T; Carbonell F; Luño E; Ardanaz M; Ramos F; Pedro C; Gomez V; de Paz R; Sanchez-Barba M; Sanz GF; Del Cañizo AC;
Cancer; 2011 Dec; 117(24):5529-37. PubMed ID: 21638279
[TBL] [Abstract][Full Text] [Related]
3. Influence of platelet count at diagnosis and during the course of disease on prognosis in MDS patients.
Strapatsas J; Barbulescu EC; Lauseker M; Kaivers J; Hildebrandt B; Nachtkamp K; Strupp C; Rudelius M; Haas R; Germing U
Ann Hematol; 2021 Oct; 100(10):2575-2584. PubMed ID: 34324021
[TBL] [Abstract][Full Text] [Related]
4. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of Platelet Recovery in Myelodysplastic Syndromes With Severe Thrombocytopenia.
Tang Y; Zhang X; Han S; Chu T; Qi J; Wang H; Tang X; Qiu H; Fu C; Ruan C; Wu D; Han Y
Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):217S-222S. PubMed ID: 30296835
[TBL] [Abstract][Full Text] [Related]
6. [A preliminary study of prognostic value of thrombocytopenia in patients with primary myelodysplastic syndromes].
Chen YD; Xu ZF; Cui R; Wang JY; Zhang TJ; Fang LW; Zhang HL; Qin TJ; Zhang Y; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2012 Jul; 33(7):532-5. PubMed ID: 22967412
[TBL] [Abstract][Full Text] [Related]
7. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
[TBL] [Abstract][Full Text] [Related]
8. The management and outcomes of patients with myelodysplastic syndrome with persistent severe thrombocytopenia: An observational single centre registry study.
Vijenthira A; Premkumar D; Callum J; Lin Y; Wells RA; Chodirker L; Lenis M; Mamedov A; Buckstein R
Leuk Res; 2019 Jan; 76():76-81. PubMed ID: 30580105
[TBL] [Abstract][Full Text] [Related]
9. The incidence and impact of thrombocytopenia in myelodysplastic syndromes.
Kantarjian H; Giles F; List A; Lyons R; Sekeres MA; Pierce S; Deuson R; Leveque J
Cancer; 2007 May; 109(9):1705-14. PubMed ID: 17366593
[TBL] [Abstract][Full Text] [Related]
10. Prognostic analysis of refractory anaemia in adult myelodysplastic syndromes.
Wang XQ; Chen ZX; Chen SC; Lin GW; Ji MR; Liang JY; Liu DD; Li DG; Ma Y
Chin Med J (Engl); 2008 Sep; 121(18):1787-91. PubMed ID: 19080358
[TBL] [Abstract][Full Text] [Related]
11. Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q- MDS (IPSS low and intermediate-1).
Jonasova A; Cermak J; Vondrakova J; Siskova M; Hochova I; Kadlckova E; Cerna O; Sykora M; Vozobulova V; Seifertova N; Michalova K; Zemanova Z; Brezinova J; Belohlavkova P; Kostecka A; Neuwirtova R
Leuk Res; 2012 Dec; 36(12):e222-4. PubMed ID: 22954608
[No Abstract] [Full Text] [Related]
12. Platelet associated IgG may be related with thrombocytopenia in patients with myelodysplastic syndromes.
Gilli SC; de Souza Medina S; de Castro V; Fernandes LG; Saad ST
Leuk Res; 2012 May; 36(5):554-9. PubMed ID: 22129476
[TBL] [Abstract][Full Text] [Related]
13. p15INK4b methylation correlates with thrombocytopenia, blast percentage, and survival in myelodysplastic syndromes in a dose dependent manner: quantitation using pyrosequencing study.
Kim M; Oh B; Kim SY; Park HK; Hwang SM; Kim TY; She CJ; Yang I; Yoon SS; Yoon JH; Lee DS
Leuk Res; 2010 Jun; 34(6):718-22. PubMed ID: 19782398
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia.
Huang QS; Wang JZ; Qin YZ; Zeng QZ; Jiang Q; Jiang H; Lu J; Liu HX; Liu Y; Wang JB; Su L; Zhang HY; Li ZL; Gao SJ; Huang B; Liu YY; Liu YR; Xu LP; Huang XJ; Zhang XH
Blood Adv; 2019 Nov; 3(21):3406-3418. PubMed ID: 31714962
[TBL] [Abstract][Full Text] [Related]
15. Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome.
Chan G; DiVenuti G; Miller K
Am J Hematol; 2002 Nov; 71(3):166-71. PubMed ID: 12410570
[TBL] [Abstract][Full Text] [Related]
16. Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes.
Mo A; Wood E; Shortt J; Hu E; McQuilten Z
Eur J Haematol; 2023 Oct; 111(4):592-600. PubMed ID: 37452616
[TBL] [Abstract][Full Text] [Related]
17. Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.
Li W; Morrone K; Kambhampati S; Will B; Steidl U; Verma A
Leukemia; 2016 Mar; 30(3):536-44. PubMed ID: 26500138
[TBL] [Abstract][Full Text] [Related]
18. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.
Kantarjian HM; Fenaux P; Sekeres MA; Szer J; Platzbecker U; Kuendgen A; Gaidano G; Wiktor-Jedrzejczak W; Carpenter N; Mehta B; Franklin J; Giagounidis A
Lancet Haematol; 2018 Mar; 5(3):e117-e126. PubMed ID: 29396092
[TBL] [Abstract][Full Text] [Related]
20. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes.
Neukirchen J; Blum S; Kuendgen A; Strupp C; Aivado M; Haas R; Aul C; Gattermann N; Germing U
Eur J Haematol; 2009 Nov; 83(5):477-82. PubMed ID: 19548919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
